Literature DB >> 6731358

Evaluation of the BACTEC 16B medium in a cancer center.

B R Tegtmeier, J L Vice.   

Abstract

The routine use of the new resin-containing BACTEC 16B (Johnston Laboratories, Inc., Cockeysville, MD) culture medium was evaluated in a population consisting primarily of cancer patients. Of 1,163 paired blood culture sets collected, 652 (56%) were collected in the presence of antimicrobial therapy. Eighty-three aerobic and facultatively anaerobic isolates were recovered from 79 positive blood culture sets. No significant difference could be demonstrated between the 16B and the 6B medium in the group of blood cultures collected from patients not receiving antibiotic therapy at the time of blood collection. In contrast, a significantly greater proportion of isolates (P less than 0.005) was recovered from the 16B medium (96%) than the 6B medium (68%) in the group of blood cultures collected in the presence of antimicrobial therapy. In this group, 43% of the isolates were either detected earlier or recovered solely from the 16B medium.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6731358     DOI: 10.1093/ajcp/81.6.783

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Effectiveness of resins in neutralizing antibiotic activities in bactec plus Aerobic/F culture medium.

Authors:  J Spaargaren; C P van Boven; G P Voorn
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

2.  Routine evaluation of BACTEC NR-16A and NR-17A media.

Authors:  R J Courcol; A V Durocher; M Roussel-Delvallez; A Fruchart; G R Martin
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

3.  Effectiveness of resins in removing antibiotics from blood cultures.

Authors:  O Crepin; M Roussel-Delvallez; G R Martin; R J Courcol
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

4.  Evaluation of new blood culture processing systems.

Authors:  J A Moody; C E Fasching; C J Shanholtzer; D N Gerding; L R Peterson
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

Review 5.  Bacteremia and fungemia in the immunocompromised patient.

Authors:  T E Kiehn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.